Anu Thummala

Abstract P2-08-20: ELCIN: Elacestrant in women and men with CDK4/6 inhibitor (CDK4/6i)-naïve estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer (mBC): An open-label multicenter phase 2 study

Virginia Kaklamani, Giorgi Dzagnidze, Nicoleta Zenovia Antone, Anu Thummala et autres

Abstract Background: Endocrine therapy plus a CDK4/6 inhibitor (ET+CDK4/6i) is the mainstay treatment in first-line ER+/HER2- mBC; however, a subset of patients is unable to tolerate CDK4/6i, and resistance to ET arises. Intrinsic resistance mechanisms include alterations in the PI3K/AKT/mTOR or cell …

ELCIN: Elacestrant in women and men with CDK4/6 inhibitor (CDK4/6i)-naïve estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer (mBC)—An open-label multicenter phase 2 study.

Virginia Kaklamani, Giorgi Dzagnidze, Nicoleta Zenovia Antone, Anu Thummala et autres

TPS1127 Background: Endocrine therapy (ET) plus a CDK4/6i is the mainstay treatment in first-line ER+/HER2- mBC; however, a subset of patients are unable to tolerate CDK4/6i, and resistance to ET emerges. Intrinsic resistance mechanisms include alterations in the PI3K/AKT/mTOR or cell cycle …

us, ro, ge, tr, it (code pays fourni par la source)

Abstract CT236: ELCIN: Elacestrant (Ela) in women and men with CDK4/6 inhibitor (CDK4/6i)- naive estrogen receptor- positive (ER+), HER2-negative (HER2-) metastatic breast cancer (mBC): An open-label multicenter phase 2 study

Virginia Kaklamani, Giorgi Dzagnidze, Nicoleta Zenovia Antone, Anu Thummala et autres

Abstract Background: Endocrine therapy (ET) plus a CDK4/6i is the mainstay treatment in 1L ER+/HER2- mBC; however, a subset of patients (pts) are unable to tolerate CDK4/6i, and resistance to ET emerges. Intrinsic resistance mechanisms include alterations in the PI3K/AKT/mTOR or cell …

us, ro, ge, tr, it (code pays fourni par la source)

Abstract PO1-04-02: ACE-Breast-03: A phase 2 study of ARX788, a novel next-generation anti-HER antibody-drug conjugate in HER2-positive metastatic breast cancer patients previously treated with trastuzumab deruxtecan

Kashif Ali, Laila Agrawal, Anu Thummala, Kevin Kalinsky et autres

Abstract Background: HER2 overexpression and/or amplification confers aggressive tumor behavior and decreased survival in patients with breast cancer. Targeting of HER2 is a validated therapeutic strategy, and trastuzumab deruxtecan (T-DXd) has emerged as a preferred treatment in the second-line setting. However, effective …

us, in (code pays fourni par la source)

Abstract CT275: A phase 2, randomized, open-label study of onvansertib in combination with standard-of-care (SoC) versus SoC alone for first-line treatment of RAS-mutant metastatic colorectal cancer (mCRC)

Heinz‐Josef Lenz, Benjamin Kuritzky, Anu Thummala, Stephan Kendall et autres

Abstract Background: Chemotherapy in combination with bevacizumab (Bev) has been a standard first-line treatment for RAS-mutated mCRC patients for the last 2 decades. The prognosis of these patients remains poor. Onvansertib is an orally available, highly potent, and selective inhibitor of Polo-like …

us (code pays fourni par la source)

Data from Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study

Antoinette R. Tan, Gail S. Wright, Anu Thummala, Michael A. Danso et autres

AbstractPurpose: We report final antitumor efficacy results from a phase II study of trilaciclib, an intravenous cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, administered prior to gemcitabine plus carboplatin (GCb) in patients with metastatic triple-negative breast cancer (NCT02978716). Patients and Methods: Patients were randomized …

Data from Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study

Antoinette R. Tan, Gail S. Wright, Anu Thummala, Michael A. Danso et autres

AbstractPurpose: We report final antitumor efficacy results from a phase II study of trilaciclib, an intravenous cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, administered prior to gemcitabine plus carboplatin (GCb) in patients with metastatic triple-negative breast cancer (NCT02978716). Patients and Methods: Patients were randomized …

Supplementary Data from Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study

Antoinette R. Tan, Gail S. Wright, Anu Thummala, Michael A. Danso et autres

Supplementary Data from Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study

Supplementary Data from Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study

Antoinette R. Tan, Gail S. Wright, Anu Thummala, Michael A. Danso et autres

Supplementary Data from Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study

Abstract PD18-09: ACE-Breast-03: Efficacy and safety of ARX788 in patients with HER2+ metastatic breast cancer previously treated with T-DM1

Sara A. Hurvitz, Kevin Kalinsky, Vinod Ganju, Kashif Ali et autres

Abstract Background: Amplification of the human epidermal growth factor receptor 2 (HER2) gene with consequent HER2 protein overexpression occurs in approximately 20% of breast cancers (BC) and is a major driver of tumor development and progression. The HER2-targeted ADC trastuzumab emtansine (T-DM1) …

us, au, in, ir, kr (code pays fourni par la source)

Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study

Antoinette R. Tan, Gail S. Wright, Anu Thummala, Michael A. Danso et autres

PURPOSE: We report final antitumor efficacy results from a phase II study of trilaciclib, an intravenous cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, administered prior to gemcitabine plus carboplatin (GCb) in patients with metastatic triple-negative breast cancer (NCT02978716). PATIENTS AND METHODS: Patients were randomized …

us, rs, hr, at, mk (code pays fourni par la source)

Abstract PD1-06: Trilaciclib improves overall survival when given with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: Final analysis of a randomized phase 2 trial

Joyce O’Shaughnessy, Gail S. Wright, Anu Thummala, Michael A. Danso et autres

Abstract Background Trilaciclib is an intravenous (IV) cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. Preliminary data showed that adding trilaciclib prior to gemcitabine plus carboplatin (GCb) significantly increased overall survival (OS) compared with GCb alone among patients with metastatic triple-negative breast cancer (mTNBC) (Tan …

us, rs, hr, at (code pays fourni par la source)